Teriflunomide
Other names:
In development for: Relapsing/remitting MS
Status: Phase III
Last updated: April 2008
How does it work?
Teriflunomide is thought to prevent the interaction of cells in the immune system involved in damage to the myelin sheath.
How is it given?
Teriflunomide is given orally as tablets.
Clinical studies
Two different doses of teriflunomide were compared to placebo in people with relapsing/remitting MS or secondary progressive MS with relapses for 36 weeks. Both doses were associated with reduced numbers of active MRI lesions and the higher dose was associated with a significantly smaller increase in disability compared to placebo. A phase III study is currently underway.
Teriflunomide is being developed by Sanofi-Aventis.
Side effects and contraindications
Treatment was well tolerated; numbers of adverse events and serious adverse events were similar in all treatment groups. Headaches and nausea were both reported.
References
O'Connor PW et al.
A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
Neurology. 2006;66(6):894-900.
Read abstract